Cultured Cells Showed Adaptation to Cannabinoid-Stimulated Prostaglandin and Arachidonate Responses

A 1985 cell-culture report found that repeated cannabinoid exposure reduced subsequent stimulation of prostaglandin E2 synthesis and arachidonic-acid release. This was biochemical adaptation in vitro, rather than a direct measure of behavioral cannabis tolerance.

The compounds and responses were identified

The reported pattern occurred with a historically named THC preparation and also with CBD and cannabicyclol. It concerned a particular metabolic response after repeated exposures, not evidence that these compounds have identical effects across all biological systems.

Two measurements supported a pathway proposal

The authors considered the arachidonic-acid result consistent with action involving lipases that regulate prostaglandin synthesis. A pattern consistent with a site of action does not establish which enzyme was responsible or exclude other contributors.

Model similarity has limits

The authors proposed the culture system as useful for investigating molecular mechanisms because it showed adaptation resembling some in-vivo patterns. A shared direction of change does not make cellular biochemical tolerance equivalent to human subjective or functional tolerance.

Interpreting the evidence

This study contributes a narrowly defined laboratory model and a mechanistic hypothesis. It does not establish an anti-inflammatory treatment, clinical dosing schedule or personal tolerance test. The measured biochemical response and in-vitro setting must remain attached to the conclusion.

Related reading: interpreting cannabis tolerance claims.

Research reference

Burstein S; Hunter SA; Renzulli L (1985). Prostaglandins and cannabis XIV. Tolerance to the stimulatory actions of cannabinoids on arachidonate metabolism. The Journal of pharmacology and experimental therapeutics. PubMed research record.

This analysis draws on the supplied study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A Pilot Mouse Study Found Declining THC and CBNA Antinociception With Repeated Administration

A 2021 pilot study reported strong initial antinociceptive responses to THC and cannabinolic acid, followed by decreasing responses over subsequent days. The evidence concerns adult male mice and experimental mechanical and thermal tests. The study evaluated two nociceptive domains Mechanical and thermal responses were assessed after systemic intraperitoneal administration. Those…

Spread the love

Read Article: A Pilot Mouse Study Found Declining THC and CBNA Antinociception With Repeated Administration

Short-Term THC–Morphine Treatment Produced Different Receptor-Protein Patterns in Mouse Midbrain and Spinal Cord

A 2001 mouse study found different opioid- and cannabinoid-receptor protein patterns across midbrain and spinal cord after short-term THC–morphine treatment. A statement about total receptor change would obscure those tissue-specific comparisons. The comparison included separate treatment groups Investigators assessed THC, morphine and their combination using Western blot measurements. Opioid-receptor protein…

Spread the love

Read Article: Short-Term THC–Morphine Treatment Produced Different Receptor-Protein Patterns in Mouse Midbrain and Spinal Cord

A THC Kinase Study Distinguished Reversing Tolerance From Reducing the Initial Drug Effect

A 2003 study found that selected kinase inhibitors reversed THC antinociceptive tolerance while others did not. One higher-dose intervention reduced THC's acute antinociceptive effect, illustrating a different outcome from reversing tolerance. The panel included useful negatives The study tested interventions directed at several kinases. Some did not affect tolerance under…

Spread the love

Read Article: A THC Kinase Study Distinguished Reversing Tolerance From Reducing the Initial Drug Effect

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us